Anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic rats: comparison with subcutaneous dosing.
The anti-osteopenic effect of nasal salmon calcitonin (SCT) was investigated in a type 1 osteoporotic model, Wistar rats which were ovariectomized (OVX) at age of 12 weeks, and compared with that of subcutaneous SCT. It was proved that nasal (5, 10, 20 and 40 U/rat) and subcutaneous (5, 10 and 20 U/kg) administration of SCT on alternate days for 3 weeks, starting a week after OVX, prevented the osteopenic changes of tibia and lumbar vertebra; this was proved by physicochemical parameters and histomorphometrically. A clear dose-dependent effect was seen in the trabecular bone volume of a selected regions of the 5th lumbar vertebra, and the ED50s of nasal and subcutaneous SCT calculated were 7.4 U/rat and 3.5 U/kg, respectively. The results indicate that nasal SCT is absorbed efficiently in rats with increased bone turnover to prevent rapidly developing osteopenia and that the administration route is a suitable standard method for chronically giving biodegradable anti-osteoporotic peptides to rats.
Ichikawa
M
M
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.
Nakamuta
H
H
Hoshino
T
T
Ogawa
Y
Y
Koida
M
M
D000281:Administration, Intranasal; D000818:Animals; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects; D002116:Calcitonin / Q000008:administration & dosage*; D002118:Calcium / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D007279:Injections, Subcutaneous; D010024:Osteoporosis / Q000188:drug therapy*; D010052:Ovariectomy; D010758:Phosphorus / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar
D010758:Phosphorus; C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium